Dipyridamol opbouw in secundaire preventie van beroerte.

A prospective randomised open label study to determine the best dose escalation schema of dipyridamole added to acetylsalicylic acid, based on the side-effect headache, in patients starting secondary preventive therapy for stroke.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON24084

Enrollment

114

Registered

2011-06-23

Start date

2011-09-15

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurology, dipyridamole, headache, stroke, neurologie, dipyridamol, hoofdpijn, beroerte, CVA, TIA

Interventions

Two study arms, 4 weeks medication. Both arms: Two weeks acetylsalicylic acid 160 mg once daily and week 3 and 4 80 mgs once daily. Further: 1. Week 1 and 2, 200 mgs dipyridamole retard once daily.

2. Week 1, 75 mgs dipyridamole once daily. Week 2, 75 mgs dipyrdidamole twice daily. Week 3, 200 mgs retard once daily and week 4 200 mgs retard twice daily.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age > 18 years; 2. Ischemic CVA or TIA; 3. Patients starting treatment with acetylsalicylic acid combined with dipyridamole accoriding to Dutch standards; 4. Able to fill out a diary.

Exclusion criteria

Exclusion criteria: Patients not starting treatment with acetylsalicylic acid and dipyrdamole according to Dutch standards.

Design outcomes

Primary

Measure	Time frame
Headache frequency.	—

Contacts

Public ContactN.C.M. Vos, de

Albert Schweitzerziekenhuis Postbus 444

n.c.m.vos-koppelaar@asz.nl+31 (0)78 6542538

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)